Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Single-arm Phase II Study of Neoadjuvant Inetetamab Combined With Pyrotinib and Nab-paclitaxel in Patients With HER2-positive Early and Locally Advanced Breast Cancer

NCT05444998 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05444998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05444998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Single-arm Phase II Study of Neoadjuvant Inetetamab Combined With Pyrotinib and Nab-paclitaxel in Patients With HER2-positive Early and Locally Advanced Breast Cancer
Lead sponsor
Xijing Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2022
Completion date
December 31, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer